Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

tiistai 12. tammikuuta 2016 päivittänyt: Hoffmann-La Roche

A Global Comparative Observational Study In Rheumatoid Arthritis (RA) Patients Who Are Treated With A TNF Inhibitor Or Tocilizumab As The First Biologic Therapy

This prospective, multi-center, observational study will assess the efficacy and safety of treatment in patients who are treated with a TNF Inhibitor or RoActemra/Actemra (tocilizumab) as the first biologic therapy. Data will be collected for 52 weeks.

Tutkimuksen yleiskatsaus

Tila

Valmis

Ehdot

Opintotyyppi

Havainnollistava

Ilmoittautuminen (Todellinen)

1225

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

  • Argentiina
      • Catamarca Capital, Argentiina, 4700
      • Mendoza, Argentiina, 5500
      • Mendoza, Argentiina, 5501
      • Rosario, Argentiina, S2000PBJ
  • Belgia
      • AYE, Belgia, 6900
      • Aalst, Belgia, 9300
      • Assebroek, Belgia, 8310
      • Bruxelles, Belgia, 1050
      • Bruxelles, Belgia, 1000
      • Edegem, Belgia, 2650
      • Genk, Belgia, 3600
      • Gent, Belgia, 9000
      • Godinne, Belgia, 5530
      • Heusy, Belgia, 4802
      • Liège, Belgia, 4000
      • Oostende, Belgia, 8400
      • Verviers, Belgia, 4800
      • Westmalle, Belgia, 2390
  • Ecuador
      • Cuenca, Ecuador
      • Esmeraldas, Ecuador, EC080150
      • Guayaquil, Ecuador, EC090114
      • Portoviejo, Ecuador
      • Quito, Ecuador, 005932
      • Quito, Ecuador, EC170135
      • Quito, Ecuador, EC170412
  • Espanja
      • Madrid, Espanja, 28006
      • Madrid, Espanja, 28905
      • Madrid, Espanja, 28007
    • Madrid
      • Fuenlabrada, Madrid, Espanja, 28942
      • San Sebastian de los Reyes, Madrid, Espanja, 28702
  • Guatemala
      • Ciudad de Guatemala, Guatemala
  • Italia
    • Abruzzo
      • Coppito, Abruzzo, Italia, 67100
      • Pescara, Abruzzo, Italia, 65100
    • Calabria
      • Reggio Calabria, Calabria, Italia, 89133
    • Campania
      • Avellino, Campania, Italia, 83100
      • Napoli, Campania, Italia, 80131
      • Napoli, Campania, Italia, 80144
      • Salerno, Campania, Italia, 84131
    • Friuli-Venezia Giulia
      • Udine, Friuli-Venezia Giulia, Italia, 33100
    • Lazio
      • Roma, Lazio, Italia, 00133
      • Roma, Lazio, Italia, 00189
    • Liguria
      • Arenzano, Liguria, Italia, 16011
    • Lombardia
      • Brescia, Lombardia, Italia, 25123
      • Legnano, Lombardia, Italia, 20025
      • Milano, Lombardia, Italia, 20157
      • Milano, Lombardia, Italia, 20162
    • Marche
      • Jesi Ancona, Marche, Italia, 60035
    • Molise
      • Agnone, Molise, Italia, 86081
    • Piemonte
      • Torino, Piemonte, Italia, 10126
      • Torino, Piemonte, Italia, 10128
    • Puglia
      • Brindisi, Puglia, Italia, 72100
      • Martina Franca, Puglia, Italia, 74015
      • San Cesario Di Lecce, Puglia, Italia, 73016
    • Sicilia
      • Catania, Sicilia, Italia, 95124
    • Toscana
      • Prato, Toscana, Italia, 59100
    • Umbria
      • Perugia, Umbria, Italia, 06122
  • Kolumbia
      • Barranquilla, Kolumbia
      • Bogota, Kolumbia
      • Bucaramanga, Kolumbia
      • Medellin, Kolumbia
  • Kreikka
      • Athens, Kreikka, 11527
      • Athens, Kreikka, 155 62
      • Patra, Kreikka, 26335
      • Thessaloniki, Kreikka, 56429
      • Thessaloniki, Kreikka, 544 65
  • Meksiko
      • Guadalajara, Meksiko, 44650
      • Guadalajara, Meksiko, 44600
      • Guadalajara, Meksiko, 45040
      • Mexicali, Meksiko, 21100
      • Mexico Ctiy, Meksiko, 07760
  • Panama
      • Panama City, Panama, 32400
  • Portugali
      • Almada, Portugali, 2801-951
      • Amadora, Portugali, 2720-276
      • Lisboa, Portugali, 1649-035
      • Lisboa, Portugali, 1069-166
      • Porto, Portugali, 4200-319
      • Porto, Portugali, 4099-001
      • Vila Nova de Gaia, Portugali, 4400-129
  • Saksa
      • Aachen, Saksa, 52064
      • Bad Aibling, Saksa, 83043
      • Bad Neuenahr-Ahrweiler, Saksa, 53474
      • Bayreuth, Saksa, 95445
      • Berlin, Saksa, 13055
      • Dresden, Saksa, 01109
      • Erfurt, Saksa, 99096
      • Erlangen, Saksa, 91056
      • Fulda, Saksa, 36043
      • Hamburg, Saksa, 22767
      • Hamburg, Saksa, 22147
      • Heidelberg, Saksa, 69121
      • Herne, Saksa, 44652
      • Köln, Saksa, 50937
      • Ludwigsfelde, Saksa, 14974
      • München, Saksa, 81541
      • München, Saksa, 80639
      • Passau, Saksa, 94032
      • Rostock, Saksa, 18059
      • Stuttgart, Saksa, 70178
      • Traunstein, Saksa, 83278
      • Wuppertal, Saksa, 42105
  • Sveitsi
      • Aarau, Sveitsi, 5000
      • Basel, Sveitsi, 4031
      • Chur, Sveitsi, 7000
      • St. Gallen, Sveitsi, 9007
  • Ukraina
      • Donetsk, Ukraina, 83045
      • Kharkiv, Ukraina, 61052
      • Kmelnytskyy, Ukraina, 29000
      • Kyiv, Ukraina, 02125
      • Kyiv, Ukraina, 03151
      • Kyiv, Ukraina, 1023
      • Odesa, Ukraina, 65026
      • Uzhgorod, Ukraina, 88000
      • Zaporizhzhya, Ukraina, 69600
  • Uruguay
      • Montevideo, Uruguay, 11000
      • Montevideo, Uruguay, 11800
  • Yhdistynyt kuningaskunta
      • Barnsley, Yhdistynyt kuningaskunta, S75 2EP
      • Basildon, Yhdistynyt kuningaskunta, SS16 5NL
      • Basingstoke, Yhdistynyt kuningaskunta, RG24 9NA
      • Brighton, Yhdistynyt kuningaskunta, BN2 5BE
      • Cannock, Yhdistynyt kuningaskunta, WS11 5XY
      • Cardiff, Yhdistynyt kuningaskunta, CF14 4XW
      • Chertsey, Yhdistynyt kuningaskunta, KT16 0PZ
      • Crawley, Yhdistynyt kuningaskunta, RH11 7DH
      • Darlington, Yhdistynyt kuningaskunta, DL3 6HX
      • Enfield, Yhdistynyt kuningaskunta, EN2 8JL
      • Grimsby, Yhdistynyt kuningaskunta, DN33 2BA
      • Guildford, Yhdistynyt kuningaskunta, GU2 7XX
      • Ipswich, Yhdistynyt kuningaskunta, IP4 5PD
      • Kettering, Yhdistynyt kuningaskunta, NN16 8UZ
      • Lancaster, Yhdistynyt kuningaskunta, LA1 4RP
      • Leeds, Yhdistynyt kuningaskunta, LS7 4SA
      • Llandudno, Yhdistynyt kuningaskunta, LL30 1LB
      • London, Yhdistynyt kuningaskunta, W6 8RF
      • London, Yhdistynyt kuningaskunta, SW17 0QT
      • London, Yhdistynyt kuningaskunta, SE18 4QH
      • Luton, Yhdistynyt kuningaskunta, LU4 0DZ
      • Maidstone, Yhdistynyt kuningaskunta, ME16 9QQ
      • Margate, Yhdistynyt kuningaskunta, CT9 4AN
      • North Shields, Yhdistynyt kuningaskunta, NE29 8NH
      • Oswestry, Yhdistynyt kuningaskunta, SY10 7AG
      • Plymouth, Yhdistynyt kuningaskunta, PL6 8DH
      • Portsmouth, Yhdistynyt kuningaskunta, PO6 3LY
      • Reading, Yhdistynyt kuningaskunta, RG1 5AN
      • Rhyl, Yhdistynyt kuningaskunta, LL18 5UJ
      • Romford, Yhdistynyt kuningaskunta, RM7 0AG
      • Sheffield, Yhdistynyt kuningaskunta, S10 2JF
      • Stockport, Yhdistynyt kuningaskunta, SK2 7JE
      • Sunderland, Yhdistynyt kuningaskunta, SR4 7TP
      • Swindon, Yhdistynyt kuningaskunta, SN3 6BB
      • Torquay, Yhdistynyt kuningaskunta, TQ2 7AA
      • Warrington, Yhdistynyt kuningaskunta, WA5 1QG
      • Wirral, Yhdistynyt kuningaskunta, CH49 5PE
      • Wolverhampton, Yhdistynyt kuningaskunta, WV10 0QP
      • Wrightington, Yhdistynyt kuningaskunta, WN6 9EP

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Näytteenottomenetelmä

Todennäköisyysnäyte

Tutkimusväestö

Adult patients with rheumatoid arthritis

Kuvaus

Inclusion Criteria:

  • Adult patients, >/=18 years of age
  • Diagnosis of rheumatoid arthritis
  • Non-respondent or intolerant to non-biologic disease-modifying anti-rheumatic drug (DMARD) therapy
  • Patient has been prescribed a first biologic therapy up to 6 weeks prior to the inclusion visit, irrespective of the treatment prescribed

Exclusion Criteria:

  • Patients whose first biologic therapy is given as part of a clinical trial studying rheumatoid arthritis (RA) treatment
  • Patients who are receiving or have received experimental DMARDs as part of a clinical trial studying RA treatment in the last 12 months
  • Patients whose first biologic is rituximab, abatacept or anakinra.
  • Patients who have received any biologic therapy for more than 6 weeks prior to the inclusion visit

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

Kohortit ja interventiot

Ryhmä/Kohortti
Kohortti

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Mean Change From Baseline in Calculated Disease Activity Score Based on 28 Joint Count Erythrocyte Sedimentation Rate at Week 24
Aikaikkuna: Baseline and Week 24
Disease activity score based on 28 joint counts (DAS28) is a composite measure of disease severity and it incorporates four specific measures of disease: swollen joint count (SJC) of 28 joints, tender joint count (TJC) of 28 joints, Patient's Global Assessment of Disease Activity by visual analogue scale (VAS), and acute-phase inflammatory marker [erythrocyte sedimentation rate (ESR) in millimeter/hour (mm/h), or C-reactive protein (CRP) in milligram/liter (mg/L)]. For the purposes of this study, ESR was used whenever possible to calculate the DAS28 (DAS28-ESR). Higher the scores, greater is the disease activity. A DAS28 score of less than or equal to (</=) 3.2 = low disease activity, a DAS28 score of >3.2 to 5.1 = moderate to high disease activity.
Baseline and Week 24

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Mean Change From Baseline in Disease Activity Score Based on 28 Joint Count Erythrocyte Sedimentation Rate at Week 52
Aikaikkuna: Baseline and Week 52
Disease activity score based on 28 joint counts (DAS28) is a composite measure of disease severity and it incorporates four specific measures of disease: swollen joint count (SJC) of 28 joints, tender joint count (TJC) of 28 joints, Patient's Global Assessment of Disease Activity by visual analogue scale (VAS), and acute-phase inflammatory marker (ESR in mm/h, or CRP in mg/L). For the purposes of this study, ESR was used whenever possible to calculate the DAS28 (DAS28-ESR). Higher the scores, greater is the disease activity. A DAS28 score of </= 3.2 = low disease activity, a DAS28 score of >3.2 to 5.1 = moderate to high disease activity.
Baseline and Week 52
Mean Change From Baseline in Erythrocyte Sedimentation Rate
Aikaikkuna: Baseline, Week 24, Week 52
Blood samples were collected for ESR, which is an acute phase reactant and a measure of inflammation. BL = baseline.
Baseline, Week 24, Week 52
Mean Change From Baseline in C-reactive Protein
Aikaikkuna: Baseline, Week 24, Week 52
Blood samples were collected for C-reactive protein (CRP). CRP is an inflammation marker. High levels of this protein indicate inflammation in diseases such as RA.
Baseline, Week 24, Week 52
Mean Change From Baseline in Swollen Joint Count
Aikaikkuna: Baseline, Week 24, Week 52
A swollen joint count (SJC) is the most specific clinical method to quantify abnormalities in participants with RA. It reflects the amount of inflamed synovial tissue. Twenty-eight joints were assessed for swelling. Joints were classified as swollen (1)/ not swollen (0) giving a total possible SJC score of 0 to 28.
Baseline, Week 24, Week 52
Mean Change From Baseline in Tender Joint Count
Aikaikkuna: Baseline, Week 24, Week 52
A tender joint count (TJC) is the most specific clinical method to quantify abnormalities in participants with RA. It is associated with the level of pain. Twenty-eight joints were assessed for tenderness. Joints were classified as tender (1)/not tender (0) giving a total possible TJC score of 0 to 28.
Baseline, Week 24, Week 52
Mean Change From Baseline in Clinical Disease Activity Index and Simplified Disease Activity Index Score
Aikaikkuna: Baseline, Week 24, Week 52
Clinical Disease Activity Index (CDAI) was calculated as the sum of the following parameters: SJC + TJC + VAS Patient Global Assessment of Disease Activity + VAS Physician Global Assessment of Disease Activity. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity'. CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. Simplified Disease Activity Index (SDAI) was calculated as the sum of the following parameters: SJC +TJC + Patient Global Assessment of Disease Activity + Physician Global Assessment of Disease Activity + CRP. SDAI scores ranged from 0 to 86, with higher scores also indicating increased disease activity.
Baseline, Week 24, Week 52
Mean Change From Baseline in Physician Global Assessment Score
Aikaikkuna: Baseline, Week 24, Week 52
The Physician's Global Assessment of disease activity was assessed using a 0 to 100 millimeter (mm) horizontal VAS. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity). Change from baseline = scores at observation minus score at baseline. An increase in score from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.
Baseline, Week 24, Week 52
Loss of Efficacy or Development of Intolerance to Biologic Therapy
Aikaikkuna: Up to Week 52
Events that are clearly consistent with the expected pattern of progression of the underlying disease may contribute to lack of efficacy. Lack of efficacy was one of the reasons for termination of biology therapy. The number of participants showing lack of efficacy to biologic therapy is presented.
Up to Week 52
Proportion of Participants Who Terminated Biologic Treatment
Aikaikkuna: Up to Week 52
The proportion of participants who discontinued biologic treatment was compared between tocilizumab-treated and TNF inhibitor-treated participants.
Up to Week 52
Reasons for Treatment Discontinuation
Aikaikkuna: Up to Week 52
The reasons for discontinuation of tocilizumab or TNF inhibitor is presented.
Up to Week 52
Cumulative Number of Participants Who Discontinued Biologic Therapy at the End of Each Study Period
Aikaikkuna: Up to end of treatment
The total number of participants who discontinued biologic therapy at the end of each study period (Week 0 - 24, Week 24 - 52, Week 52 - 57 and Week 57 - end of treatment) is presented. Participants who did not have a biologic therapy discontinuation or discontinued before having one, were considered as 'censored' at the date study termination.
Up to end of treatment
Number of Participants of Infusion Reactions or Injection Site Reactions During the Study Following the Start of the First Biologic Therapy
Aikaikkuna: Up to Week 52
An infusion reaction was defined as an adverse event (AE) occurring during and within 24 hours after the infusion, which may include hypersensitivity reactions or anaphylactic reactions. Injection site reactions were included in the summaries for infusion reactions.
Up to Week 52
Number of Participants With Adverse Events, Serious Adverse Events and Non-serious Adverse Events
Aikaikkuna: Up to Week 52
An AE is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.
Up to Week 52
Number of Participants With Serious and Non-serious Adverse Events of Special Interest, Including Infections, During the Study
Aikaikkuna: Up to Week 52
Adverse events of special interest (AESI) for this study included: infections (including opportunistic infections), myocardial infarction/acute coronary syndrome, gastrointestinal perforation and related events, malignancies, anaphylaxis / hypersensitivity reactions, demyelinating disorders, stroke, bleeding events and hepatic events. Based on seriousness criteria, they were categorized as serious and non-serious adverse events of special interest.
Up to Week 52
Mean Change From Baseline in Health Assessment Questionnaire Disability Index Score
Aikaikkuna: Baseline, Week 24, Week 52
The Health Assessment Questionnaire-Disability Index (HAQ-DI) is a 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping and activities of daily living). Responses in each functional area are scored from 0 to 3 (0=no difficulty and 3=inability to perform a task in that area). HAQ-DI total scores expressed as overall mean score with range 0-3: 0-0.25=normal functioning; 0.25-0.5=mild functional limitation; 0.5-1=moderate functional limitation; more than 1=significant functional limitation.
Baseline, Week 24, Week 52
Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue Score
Aikaikkuna: Baseline, Week 24, Week 52
Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participant's fatigue. The sum of all responses resulted in the FACIT-F score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflects an improvement in the participant's health status.
Baseline, Week 24, Week 52
Mean Change From Baseline in Visual Analogue Scale Pain Score
Aikaikkuna: Baseline, Week 24, Week 52
VAS is a 100 mm scale. Intensity of pain range: 0 mm=no pain to 100 mm=worst possible pain. Change from baseline =scores at observation minus score at baseline. An increase in score from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.
Baseline, Week 24, Week 52
Shift From Baseline in Morning Stiffness
Aikaikkuna: Baseline, Week 24, Week 52
Shift tables presenting the number of participants in each bivariate category Week (W) 0 versus Week 24 and Week 52, with regards to morning stiffness at the different time points, was presented for each treatment arm. For participants who experienced joint stiffness while waking up in the morning, duration of morning stiffness was categorized as follows: Less than 30 minutes (min), Between 30 and 60 minutes, Between 60 and 120 minutes, Between 120 to 240 minutes, More than 240 minutes and the whole day. Baseline = BL
Baseline, Week 24, Week 52
Change From Baseline in Patient Global Assessment of Disease Activity
Aikaikkuna: Baseline, Week 24, Week 52
The patient's global assessment of disease activity is assessed on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity). A negative change from Baseline indicated improvement.
Baseline, Week 24, Week 52

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Hoffmann-La Roche

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Yleiset julkaisut

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus

Keskiviikko 1. helmikuuta 2012

Ensisijainen valmistuminen (Todellinen)

Sunnuntai 1. helmikuuta 2015

Opintojen valmistuminen (Todellinen)

Sunnuntai 1. helmikuuta 2015

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Tiistai 28. helmikuuta 2012

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Tiistai 28. helmikuuta 2012

Ensimmäinen Lähetetty (Arvio)

Maanantai 5. maaliskuuta 2012

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Arvio)

Keskiviikko 10. helmikuuta 2016

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Tiistai 12. tammikuuta 2016

Viimeksi vahvistettu

Perjantai 1. tammikuuta 2016

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muita asiaankuuluvia MeSH-ehtoja

Muut tutkimustunnusnumerot

  • MA27950

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa